

, Oct-14-03 05:04pm From-Affymetrix, Inc.

408 731 5392

T-631 P.004/007 F-199

PATENT  
Attorney Docket No. 3379.1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David C. Kulp, et al.

Examiner: John D. Ulm

Serial No: 10/038,895

Art Unit No.: 1646

Filing Date: October 24, 2001

Title: **Nucleic Acid Encoding G  
Protein-Coupled Receptors**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**RESPONSE AND AMENDMENT TO RESTRICTION REQUIREMENT**

Sir:

In response to the Office Action mailed September 4, 2003 Office Action, Applicants respectfully request reconsideration of the pending rejections and reexamination of the present application in view of the following remarks.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

PATENT  
Attorney Docket No. 3379.1

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (currently amended) An isolated polynucleotide comprising a the nucleic acid sequence shown in any one of Figure 1B Figures 1C, 1D, 2B, 3B, 4B, 5B, 6B, 7B, 8B, and 9B.

Claims 2 -54 (canceled)

PATENT  
Attorney Docket No. 3379.1

REMARKS/ARGUMENTS

*Sequence Listing under 37 C.F.R. §§ 1.821 through 1.825*


A Substitute Sequence Listing in paper and electronic formats with an amendment directing the entry of that paper copy into the specification and a statement indicating that the content of the paper and electronic copy are the same as required was filed on March 20, 2003 by the Applicants. A preliminary amendment to the specification adding the corresponding Sequence Identifiers as required by C.F.R. 37 § 1.821(d) was filed by the Applicants on February 19, 2003. Reconsideration and withdrawal of the objection is respectfully requested.

*Election/Restrictions under 35 U.S.C. 121*

Applicants hereby elect to prosecute the invention of Group I (claims 1, 11 to 30 and 53) as they relate to the nucleotide sequence presented in Figure 1B. Applicants herein cancel claims 2-54 to expedite prosecution of the remaining claim. Applicants reserve the right to re-present non-elected claims in a divisional or other related application.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 01-0431.

Respectfully submitted,



Sandra E. Wells  
Reg. No.: 52,349

Date: 10/13/2003

Customer No.: 22886  
Affymetrix, Inc.,  
Legal Department  
3380 Central Expressway  
Santa Clara, CA 95051  
Tel: 408/731-5000; Fax: 408/731-5392